Concerns about an increased risk of bone fractures and heart attacks for patients taking thiazoladinedione drugs for type 2 diabetes have been put in perspective by the European Medicines Agency (EMEA),following a review of evidence.The EMEA has concluded that the benefits of rosiglitazone and pioglitazone continue to outweigh the products' risks for the approved indications.
展开▼
